Connect with us

Hi, what are you looking for?

RiseInTheFuture.comRiseInTheFuture.com

Editor's Pick

Swenlin Trading Oscillators Trying To Turn Up

It was ultimately a decent rally today on the SP500 with help from the tech heavy Nasdaq. Swenlin Trading Oscillators (STOs) are our primary short-term indicators. They have been in decline for all of the indexes, but we noted a few trying to turn up. The SPY saw a rise in the Swenlin Trading Oscillator for volume (STO-V), but not the Swenlin Trading Oscillator for Breadth (STO-B). The Nasdaq (ONEQ) saw the opposite with the STO-B rising, but STO-V still falling. Both have turned up for the SP600 (IJR).

As noted above, only the STO-V turned up for the SPY, but another rally will likely push the STO-V up as well. The intermediate-term ITBM and ITVM are not confirming this short-term bullish condition on the STO-B.


August Summer Sale is On!

Buy One Month and Get One Month FREE!

No coupon code is required. Sale ENDS August 31st! No exceptions!


All other major indexes with the exception of the Nasdaq and SP600 continue to see lower readings. It isn’t completely surprising to see the Nasdaq improving given the rally today. However, only the STO-B turned up on the Nasdaq. Notice that all the other indicators remain in decline.

We were asked today in the DecisionPoint Trading Room about STOs for the small-caps. The SP600 (IJR) actually looks healthier than both the Nasdaq and SPY given its Swenlin Trading Oscillators began turning up on Friday. We still don’t have confirmation from our intermediate-term indicators, but this is a very interesting development, particularly given the lackluster performance today. Again, no confirmation by the ITBM and ITVM to be seen.

Conclusion: Our primary short-term indicators (STOs) are beginning to show a few signs of life. Seeing the broader SP600 improvement under the surface is encouraging for the rest of the market. We would caution this is early and our sense is that we are about to see a pause in the decline, particularly given the NYSE isn’t showing signs of improvement.

You May Also Like

Editor's Pick

Jeffrey A. Singer On the same day that the Food and Drug Administration allowed women over‐​the‐​counter access to one progestin‐​only birth control pill, Rep....

Editor's Pick

Jack Solowey and Jennifer J. Schulp Last Wednesday, July 12, an updated version of the Lummis‐​Gillibrand Responsible Financial Innovation Act (RFIA) became public. The...

Editor's Pick

Jeffrey A. Singer The Food and Drug Administration announced this morning that it has granted marketing approval for the over‐​the‐​counter sale of one type...

Editor's Pick

Walter Olson A widely noted new draft paper by two political scientists, Justin Grimmer of Stanford and Eitan Hersh of Tufts, surveys existing research...